secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001104659-23-066311
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics reports pre-clinical data showing MT-601 kills CD19 CAR T refractory lymphoma cells
--------------------------------------------------------------------------------

- In vitro, MT-601 completely inhibited growth of lymphoma cells resistant to CD19 CAR T therapy after 3 weeks.
- Initial CAR T administration eliminated 98% of lymphoma cells; resistant population emerged; MT-601 overcame resistance.
- MT-601 targets six antigens (including WT-1) vs. five in earlier TACTAL study, potentially offering more durable responses.
- FDA cleared IND for MT-601; Phase 1 trial in relapsed non-Hodgkin lymphoma initiated Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923066311/0001104659-23-066311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923066311/tm2317378d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-066311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer